Search results for "Exacerbation"

showing 10 items of 164 documents

COPD in elderly patients – an analysis of the DACCORD observational study

2018

Introduction: In elderly patients COPD is frequently complicated by the presence of several comorbidities and the many non-COPD-related medications prescribed to treat these conditions. This analysis aims to characterize COPD patients above the age of 75 in a real-world cohort in Germany. Methods: DACCORD is a prospective, non-interventional study collecting data from COPD patients treated in primary and secondary care. Prior to study entry, patients either initiated or changed COPD maintenance medication. Moderate/severe exacerbations, COPD-medication and non-COPD medication were documented at baseline and every 3 months. Comorbidities were documented at baseline. Results: Baseline charact…

PolypharmacyCOPDmedicine.medical_specialtyExacerbationbusiness.industrymedicine.medical_treatmentmedicine.diseaserespiratory tract diseasesSecondary careInternal medicineCohortMedicineSmoking cessationIn patientObservational studybusinessClinical Problems
researchProduct

P294 Benefits of tiotropium/olodaterol over tiotropium at delaying clinically significant events in patients with copd classified as gold B

2016

Rationale The once-daily combination of tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β 2 -agonist, has demonstrated efficacy and safety in COPD. Two large clinical studies (TONADO ® 1 + 2) have also demonstrated the benefits of T/O compared to the monocomponents in patients with moderate to very severe COPD. This post hoc analysis investigated whether T/O is more effective than T at delaying clinically significant events in patients with GOLD stage B COPD. Methods A total of 5162 patients were randomised to O 5 µg, T 2.5 µg, T 5 µg, T/O 2.5/5 µg or T/O 5/5 µg (delivered via Respimat ® inhaler) in two 52-week, parallel-group, double-blind studies (NC…

Pulmonary and Respiratory Medicine030213 general clinical medicineCOPDmedicine.medical_specialtyRespimatExacerbationbusiness.industryInhalerOlodaterolmedicine.diseaseGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisInternal medicinePost-hoc analysismedicineIn patientRespiratory systembusinessThorax
researchProduct

Inspiratory Effort and Respiratory Mechanics in Patients with Acute Exacerbation of Idiopathic Pulmonary fibrosis: A Preliminary Matched Control Stud…

2022

Background: Patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) may experience severe acute respiratory failure, even requiring ventilatory assistance. Physiological data on lung mechanics during these events are lacking. Methods: Patients with AE-IPF admitted to Respiratory Intensive Care Unit to receive non-invasive ventilation (NIV) were retrospectively analyzed. Esophageal pressure swing (ΔPes) and respiratory mechanics before and after 2 hours of NIV were collected as primary outcome. The correlation between positive end-expiratory pressure (PEEP) levels and changes of in dynamic compliance (dynCRS) and PaO2/FiO2 ratio was assessed. Further, an exploratory compar…

Pulmonary and Respiratory MedicineAcute exacerbation of idiopathic pulmonary fibrosiEsophageal pressure swingEsophageal manometryARDSNon-invasive mechanical ventilationInspiratory effortRespiratory mechanics.Acute respiratory failureDynamic transpulmonary pressurePulmonology
researchProduct

Asthma exacerbations and socio-economic status in French adults with persistent asthma: A prospective cohort study.

2017

Adults disadvantaged by poor socio-economic status (SES) are more severely affected by asthma compared to those with better SES. We aimed to determine whether the frequency of asthma exacerbations (AEx), as well as aspects related to AEx management, differed based on SES in patients treated with daily treatments.This study, part of the prospective observational cohort ASTRO-LAB, included French adult patients with persistent asthma. Patients were considered as low SES if they benefited from publicly funded special health insurance and/or were perceived as low SES by their general practitioner. AEx was defined as at least one of the following: asthma-related oral corticosteroid course, medic…

Pulmonary and Respiratory MedicineAdultHypersensitivity ImmediateMalePediatricsmedicine.medical_specialtyAdolescentGeneral PracticeComorbiditySeverity of Illness IndexBody Mass Index03 medical and health sciencesYoung Adult0302 clinical medicineImmunology and AllergyMedicineHumans030212 general & internal medicineSocial determinants of healthAnti-Asthmatic AgentsProspective StudiesProspective cohort studySocioeconomic statusAsthmaAsthma exacerbationsMedical Assistancebusiness.industrysocial sciencesmedicine.diseaseAsthma030228 respiratory systemSocioeconomic FactorsPediatrics Perinatology and Child HealthCohortpopulation characteristicsObservational studyFemaleFrancebusinessEmergency Service HospitalCohort studyThe Journal of asthma : official journal of the Association for the Care of Asthma
researchProduct

Sociodemographic factors associated with time to discharge for hospitalised patients with asthma and asthma exacerbation using the Ghana Health Servi…

2021

ObjectiveData on asthma hospitalisations are a useful source of patient morbidity information. In Ghana, the length of stay (LoS) and sociodemographic factors of patients hospitalised for asthma and its exacerbation are understudied. We aimed to investigate the time to discharge and assessed factors associated with length of hospital stays of asthmatics in Ghana.MethodsRetrospective analysis of hospitalised patient with asthma records between 2012 and 2017 from the nationwide Ghana Health Service District Health Information Management System 2 database. We calculated the cumulative incidence function for discharge stratified by age group and sex. Multivariable Cox regression was used to inv…

Pulmonary and Respiratory MedicineAdultSociodemographic FactorsExacerbationInformation Managementcomputer.software_genreGhanaHealth servicesDiseases of the respiratory systemHealth caremedicineHumans1506ChildEarly dischargeAsthmaRetrospective StudiesAsthma exacerbationsDatabaseRC705-779business.industryProportional hazards modelasthma epidemiologyRmedicine.diseaseComorbidityAsthmaPatient DischargeCOPD exacerbationsMedicineFemalebusinesscomputerBMJ Open Respiratory Research
researchProduct

Does the frequency of switching inhalers represent a predictive factor of exacerbation in asthma?

2020

Objective: Management of asthma includes monitoring of inhaler technique and level of adherence to treatment. Both factors could be influenced by high frequency of switching inhaler devices. We explored whether switching inhalers is an independent predictive factor of exacerbations. Methods: Data were collected from 2015 to 2017 from the outpatient clinic of asthma at the University of Palermo, Italy. This observational study consisted of two phases: Phase 1 included subjects of at least three visits in the previous year who reported the frequency of inhalers switched; Phase 2 included subjects of at least two visits during the second year, and the rate of switches and exacerbations was rec…

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtyExacerbationSettore MED/10 - Malattie Dell'Apparato Respiratorioexacerbation: inhaler03 medical and health sciencesYoung Adult0302 clinical medicineAdrenal Cortex HormonesAdministration InhalationmedicineImmunology and AllergyHumans030212 general & internal medicineAnti-Asthmatic AgentsIntensive care medicinedeviceAsthmaAgedAged 80 and overbusiness.industryInhalerNebulizers and VaporizersMiddle Agedmedicine.diseaseAsthmaswitchPredictive factorHospitalization030228 respiratory systemPediatrics Perinatology and Child Healthbusiness
researchProduct

The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever u…

2012

Abstract Background Divergent strategies have emerged for the management of severe asthma. One strategy utilises high and fixed doses of maintenance treatment, usually inhaled corticosteroid/long-acting β2-agonist (ICS/LABA), supplemented by a short-acting β2-agonist (SABA) as needed. Alternatively, budesonide/formoterol is used as both maintenance and reliever therapy. The latter is superior to fixed-dose treatment in reducing severe exacerbations while achieving similar or better asthma control in other regards. Exacerbations may be reduced by the use of budesonide/formoterol as reliever medication during periods of unstable asthma. We examined the risk of a severe exacerbation in the per…

Pulmonary and Respiratory MedicineBudesonideExacerbationAsthma in primary careSeverity of Illness Indexlaw.inventionRandomized controlled trialDouble-Blind MethodlawAdrenal Cortex HormonesRisk FactorsFormoterol FumarateAdministration InhalationmedicineBudesonide Formoterol Fumarate Drug CombinationHumansAnti-Asthmatic AgentsBudesonideAsthmalcsh:RC705-779Maintenance dosebusiness.industryResearchlcsh:Diseases of the respiratory systemmedicine.diseaseAsthmaBronchodilator AgentsDrug CombinationsTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDisease ProgressionFormoterol FumarateDrug Therapy CombinationFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugRespiratory research
researchProduct

Oxidative Stress and Respiratory System: Pharmacological and Clinical Reappraisal of N-Acetylcysteine

2014

Abstract The large surface area for gas exchange makes the respiratory system particularly susceptible to oxidative stress-mediated injury. Both endogenous and exogenous pro-oxidants (e.g. cigarette smoke) trigger activation of leukocytes and host defenses. These mechanisms interact in a ìmultilevel cycleî responsible for the control of the oxidant/antioxidant homeostasis. Several studies have demonstrated the presence of increased oxidative stress and decreased antioxidants (e.g. reduced glutathione [GSH]) in subjects with chronic obstructive pulmonary disease (COPD), but the contribution of oxidative stress to the pathophysiology of COPD is generally only minimally discussed. The aim of t…

Pulmonary and Respiratory MedicineChronic ObstructiveAntioxidantantioxidantNeutrophilsmedicine.medical_treatmentAntioxidant; Copd exacerbation; Lung function; Small airways; Acetylcysteine; Antioxidants; Bronchitis Chronic; Disease Progression; Expectorants; Forced Expiratory Volume; Hospitalization; Humans; Macrophages; Neutrophils; Pulmonary Disease Chronic Obstructive; Reactive Oxygen Species; Respiratory Physiological Phenomena; Oxidative Stress; Pulmonary and Respiratory MedicineAntioxidant; Copd exacerbation; Lung function; Small airways; Acetylcysteine; Antioxidants; Bronchitis Chronic; Disease Progression; Expectorants; Forced Expiratory Volume; Hospitalization; Humans; Macrophages; Neutrophils; Pulmonary Disease Chronic Obstructive; Reactive Oxygen Species; Respiratory Physiological Phenomena; Oxidative StressOxidative phosphorylationReviewSettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.disease_causeAntioxidantsAcetylcysteinePulmonary Diseasechemistry.chemical_compoundPulmonary Disease Chronic ObstructiveCOPD exacerbationForced Expiratory VolumemedicineHumansRespiratory systemChronicBronchitisExpectorantschemistry.chemical_classificationCOPDReactive oxygen speciessmall airwaysbusiness.industryMacrophageslung functionGlutathionemedicine.diseaseAcetylcysteineBronchitis ChronicHospitalizationOxidative StresschemistryImmunologyDisease ProgressionRespiratory Physiological PhenomenabusinessReactive Oxygen SpeciesOxidative stressmedicine.drug
researchProduct

Phenotypes contribute to treatments.

2017

Chronic obstructive pulmonary disease (COPD) represents a major health problem in Central and Eastern European (CEE) countries; however, there are no data regarding clinical phenotypes of these patients in this region. Participation in the Phenotypes of COPD in Central and Eastern Europe (POPE) study was offered to stable patients with COPD in a real-life setting. The primary aim of this study was to assess the prevalence of phenotypes according to predefined criteria. Secondary aims included analysis of differences in symptom load, comorbidities and pharmacological treatment. 3362 patients with COPD were recruited in 10 CEE countries. 63% of the population were nonexacerbators, 20.4% frequ…

Pulmonary and Respiratory MedicineChronic bronchitismedicine.medical_specialtyExacerbation1InflammationDisease03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInternal medicinemedicineHumansCOPD030212 general & internal medicineCOPDbusiness.industryOriginal Articlesmedicine.diseasePhenotypeObstructive lung diseaserespiratory tract diseasesPhenotype030228 respiratory systemImmunologymedicine.symptomAirwaybusinessThe European respiratory journal
researchProduct

Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease

2005

Current therapy for chronic obstructive pulmonary disease (COPD) fails to alter its relentless progression. This remains a significant challenge and unmet need. A recent advance is the demonstration that treatment with a fixed dose of an inhaled corticosteroid and a long-acting beta2-agonist in COPD improves lung function and quality of life, and reduces exacerbation more effectively than either drug alone. Other improvements include the introduction of tiotropium, a once-daily anticholinergic. In advanced clinical development are other once-daily bronchodilators and combinations of anticholinergic drugs and beta2-agonists. Increased understanding of the pathogenesis of COPD has led to nove…

Pulmonary and Respiratory MedicineDrugmedicine.medical_specialtyExacerbationPhosphodiesterase Inhibitorsmedicine.drug_classmedia_common.quotation_subjectAnti-Inflammatory AgentsPharmacologySystemic inflammationAntioxidantsPathogenesisPulmonary Disease Chronic ObstructiveAdministration InhalationAnticholinergicmedicineHumansProtease InhibitorsIntensive care medicineGlucocorticoidsmedia_commonCOPDInhalationbusiness.industryAntibodies MonoclonalAdrenergic beta-Agonistsmedicine.diseaseBronchodilator Agentsrespiratory tract diseasesDrug developmentQuality of LifeSmoking Cessationmedicine.symptombusinessProceedings of the American Thoracic Society
researchProduct